Product information and disease descriptionProduct descriptionProduct information
Contraindications/Warnings/Precautions/Adverse effects
16 evidence topics · 10 sources
Warnings and precautions
FDA-approved prescribing information, contraindications, and boxed warnings
Not applicable.
Adverse events of special interest: Launch-HTN
“Prespecified adverse events of special interest included dose reduction, interruption, or discontinuation due to hyperkalemia, hyponatremia, and reduction in kidney function (decline in eGFR) as well as treatment discontinuation due to glucocorticoid deficiency, symptomatic hypotension, severely elevated BP, or overdose of trial drug or prescribed antihypertensive medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prespecified adverse events of hyponatremia, hyperkalemia, and reduction in kidney function (decline in eGFR) were reported more with lorundrostat compared with placebo; however, few treatment discontinuations occurred due to these events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hyperkalemia: Launch-HTN
“A serum potassium level of greater than 6.0 mmol/L occurred in 4 participants (1.5%) randomized to 50 mg of lorundrostat group with possible dose escalation to 100 mg, in 6 participants (1.1%) randomized to 50 mg of lorundrostat, and in 2 participants (0.7%) randomized to placebo” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean serum potassium level increased in the 2 lorundrostat groups but remained within normal range” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hyperkalemia: Advance-HTN
“A potassium level above 6.0 mmol per liter occurred in 5 participants (5%) in the stable-dose group, 7 participants (7%) in the dose-adjustment group, and no participants in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Hyperkalemia: Target-HTN
“Mean serum potassium increases were similar across all lorundrostat doses, including increases of 0.25 mmol/L in the 50-mg and 100-mg once-daily groups. Six participants (3.6%) had serum potassium levels above 6.0 mmol/L during the trial” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No instances of hyperkalemia required intervention beyond discontinuation or reduction in the dose of lorundrostat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lorundrostat has a relatively short half-life, and once-daily dosing resulted in a 25% lower mean change in serum potassium when 50 mg once daily was compared with 25 mg twice daily.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hyperkalemia: Explore-CKD
Adverse events during 36 weeks of open-label treatment: Transform-HTN
| Event | Lorundrostat (N=632), n (%) |
|---|---|
| Any serious adverse event | “27 (4.3)” |
| Treatment-emergent adverse event leading to study drug withdrawal | “37 (5.9)” |
| Hyperkalemia leading to study drug withdrawal | “10 (1.6)” |
| Hyperkalemia requiring modification of trial drug | “32 (5.1)” |
| Hyponatremia requiring modification of trial drug | “28 (4.4)” |
| Hypotension with symptoms | “13 (2.1)” |
| Serum potassium >6.0 mmol/L confirmed by repeat testing | “16 (2.5)” |
Hyponatremia
“Among participants in the 50 mg of lorundrostat group with possible escalation to 100 mg, treatment discontinuation occurred in 1 (0.37%) due to hyperkalemia, in 1 (0.37%) due to hyponatremia, and in 0 due to reduction in kidney function (decline in eGFR). Among participants in the 50 mg of lorundrostat group, treatment discontinuation occurred in 2 (0.37%) due to hyperkalemia, in 2 (0.37%) due to hyponatremia, and in 3 (0.56%) due to reduction in kidney function (decline in eGFR).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events in Advance-HTN
Decline in estimated glomerular filtration rate
“Creatinine-based eGFR decreased by 9.3% from baseline to week 12 in the 2 lorundrostat groups and increased by 0.4% in the placebo group. Using the cystatin-C–based eGFR formula, eGFR decreased by 5.2% in the 50 mg of lorundrostat group with possible escalation to 100 mg, decreased by 4.1% in the 50 mg of lorundrostat group, and increased by 3.4% in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An acute, reversible decline in eGFR of similar or greater magnitude has also been observed with renin-angiotensin-aldosterone system inhibitors and sodium glucose cotransporter inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Declines in eGFR paralleled the reduction in systolic AOBP and were consistent with expected lowering of intraglomerular pressures” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adrenal insufficiency and cortisol
“The treatment-emergent adverse event of glucocorticoid insufficiency was reported in 0 participants in the 50 mg of lorundrostat group with possible escalation to 100 mg, in 3 participants (0.56%) in the 50 mg of lorundrostat group, and in 5 participants (1.9%) in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no reports of hyperadrenocorticism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 12, the geometric mean for serum cortisol increased by 4.2% from baseline in the 50 mg of lorundrostat group with possible escalation to 100 mg, increased by 5.0% in the 50 mg of lorundrostat group, and decreased by 2.0% in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No adrenocortical insufficiency occurred during the trial. Cosyntropin stimulation testing in participants randomized to 100 mg once daily in both cohort 1 and cohort 2 was normal, with stimulated values of cortisol greater than 18 µg/dL in all individuals receiving cosyntropin” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events in healthy participants: first-in-human study
“Lorundrostat was well tolerated and no serious TEAEs occurred during the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall incidence of TEAEs was comparable between participants treated with lorundrostat (41/87 [47%]) and those treated with placebo (18/29 [62%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“None of the subjects reached the stopping criterion for potassium of 6.0 mmol/L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote